Hostname: page-component-797576ffbb-5676f Total loading time: 0 Render date: 2023-12-10T11:52:21.243Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false

EPA-1690 – Cannabis Use is Associated with Biological Markers of Ageing in Healthy Volunteers

Published online by Cambridge University Press:  15 April 2020

L. Scoriels
Psychiatry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
S. Theegala
Psychiatry, University of Cambridge, Cambridge, United Kingdom
M. Giro
Mental Health, Universitària Parc Tauli de Sabadell, Barcelona, Spain
S. Ozanne
Metabolic Research Laboratories, University of Cambridge, Cambridge, United Kingdom
K. Burling
Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom
P.B. Jones
Psychiatry, University of Cambridge, Cambridge, United Kingdom
E. Fernandez-Egea
Psychiatry, University of Cambridge, Cambridge, United Kingdom
Get access



Cannabis is a widely used drug, which effects on human health remain controversial. Recent studies have found correlations between cannabis use and brain structural changes that may be related to ageing processes. Eotaxin-1 is a chemokine described as a marker of ageing, which also appear to increase with cognitive deficits and neurogenesis. Here, we aimed at characterising the effect of cannabis in accelerating normal ageing processes, by studying eotaxin-1 plasma levels in people who currently use cannabis, have used cannabis in the past, or have never used cannabis.


A total of 87 healthy volunteers participated in the study. Participants completed the Cannabis Experience Questionnaire, the General Practice Physical Activity Questionnaire, the Sociodemographic, Morphometric, Alcohol and Tobacco Questionnaire, and provided a blood sample. Eotaxin-1 was assessed by ELISA. The three groups were compared using one-way ANOVA to assess levels of eotaxin-1, and nonpaired Student t-tests to assess other factors effects.


Current users of cannabis (n=18) had significantly higher eotaxin-1 plasma levels compared to past users of cannabis (n=33) and individuals who never used cannabis (n=36). The latter two groups had similar eotaxin-1 levels. Higher eotaxin-1 plasma levels were not attributed to gender, age, body mass index, physical activity or use of other legal/illegal drugs.


These results suggest that cannabis use increases eotaxin-1 plasma levels and could result in accelerated brain ageing. However, the effects appear to be reversible when cannabis use ceases. These findings have important implications for treatment and care of mental health disorders, such as schizophrenia.

P01 - Addictive Behaviours
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response


No Comments have been published for this article.